Telaprevir’s Hidden Talents: New Data Show Effectiveness In Difficult To Cure Populations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Groups with historically poor responses to standard hepatitis C therapy made good progress when the direct-acting antiviral telaprevir was added to their regimen, Vertex Pharmaceuticals Inc. reported at the American Association for the Study of Liver Diseases Meeting in Boston.